Jazz Pharmaceuticals (JAZZ) 10K Form and Latest SEC Filings 2026

Jazz Pharmaceuticals logo
$236.22 -11.55 (-4.66%)
Closing price 03:59 PM Eastern
Extended Trading
$236.40 +0.18 (+0.08%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Jazz Pharmaceuticals SEC Filings & Recent Activity

Jazz Pharmaceuticals (NASDAQ:JAZZ) has submitted 760+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Jazz Pharmaceuticals's financial statements. The most recent filing was a Form 4 submitted on November 10, 2026.

Form 4
Jazz Pharmaceuticals plc Reports Ownership Change on Nov. 10, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Jazz Pharmaceuticals Files Current Report on Oct. 26, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Jazz Pharmaceuticals Files Annual Report on Feb. 24, 2026

The 10-K contains Jazz Pharmaceuticals's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Jazz Pharmaceuticals SEC Filing History

Browse Jazz Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
11/10/2026 3:46 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2026 4:19 PM
Carr Patricia (1784606) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2026 3:41 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/05/2026 5:28 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2026 12:19 PM
FMR LLC (315066) Filed by
Jazz Pharmaceuticals (1232524) Subject
Form SCHEDULE 13G/A
11/04/2026 5:35 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2026 3:23 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/26/2026 3:03 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2026 8:02 AM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/08/2026 3:04 PM
Jazz Pharmaceuticals (1232524) Subject
ORiordan Anne (1767870) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/07/2026 4:44 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2026 3:20 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/05/2026 3:18 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2026 3:32 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/23/2026 3:15 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/15/2026 8:06 AM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/14/2026 5:38 PM
Jazz Pharmaceuticals (1232524) Issuer
Patil Neena M (1783908) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2026 3:28 PM
Henderson Mary Elizabeth (1989533) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2026 3:33 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2026 3:06 PM
Jazz Pharmaceuticals (1232524) Subject
Patil Neena M (1783908) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2026 3:37 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2026 1:27 PM
Henderson Mary Elizabeth (1989533) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/02/2026 4:38 PM
Henderson Mary Elizabeth (1989533) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:06 PM
Jazz Pharmaceuticals (1232524) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:24 PM
Hamill Laura (1751804) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:28 PM
Jazz Pharmaceuticals (1232524) Issuer
LOVE TED W (1188919) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:31 PM
Jazz Pharmaceuticals (1232524) Issuer
RIEDEL NORBERT G (1161662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:34 PM
Jazz Pharmaceuticals (1232524) Issuer
Smith Mark Douglas (1756253) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:09 PM
Jazz Pharmaceuticals (1232524) Issuer
Kennedy Patrick (2013944) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:13 PM
Jazz Pharmaceuticals (1232524) Issuer
McSharry Heather Ann (1576068) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:17 PM
ENRIGHT PATRICK G (1253886) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:20 PM
Cook Jennifer E. (1754371) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2026 4:03 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/01/2026 3:21 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 5:45 PM
Iannone Robert (1737329) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/31/2026 4:21 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/31/2026 4:04 PM
Jazz Pharmaceuticals (1232524) Subject
LOVE TED W (1188919) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 3:51 PM
Jazz Pharmaceuticals (1232524) Subject
Winningham Rick E (1302443) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 3:33 PM
ENRIGHT PATRICK G (1253886) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 3:14 PM
Jazz Pharmaceuticals (1232524) Subject
Smith Mark Douglas (1756253) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 2:41 PM
Hamill Laura (1751804) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
The investigation Porter spent tens of thousands to document (Ad)

Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel

Watch the full investigation and decide for yourself
08/31/2026 2:50 PM
Henderson Mary Elizabeth (1989533) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 2:26 PM
Jazz Pharmaceuticals (1232524) Subject
McSharry Heather Ann (1576068) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 2:36 PM
Cook Jennifer E. (1754371) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/31/2026 2:10 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/27/2026 3:31 PM
Iannone Robert (1737329) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/25/2026 3:06 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/10/2026 4:13 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/10/2026 6:40 AM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2026 4:55 PM
Jazz Pharmaceuticals (1232524) Issuer
LOVE TED W (1188919) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:57 PM
Jazz Pharmaceuticals (1232524) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 5:01 PM
Jazz Pharmaceuticals (1232524) Issuer
Pearce Samantha (1805688) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:39 PM
Jazz Pharmaceuticals (1232524) Issuer
McSharry Heather Ann (1576068) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:42 PM
Jazz Pharmaceuticals (1232524) Issuer
Mulligan Seamus (1536639) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:44 PM
Cook Jennifer E. (1754371) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:46 PM
Jazz Pharmaceuticals (1232524) Issuer
Smith Mark Douglas (1756253) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:48 PM
Jazz Pharmaceuticals (1232524) Issuer
Kennedy Patrick (2013944) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:50 PM
Hamill Laura (1751804) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:31 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:33 PM
Jazz Pharmaceuticals (1232524) Issuer
RIEDEL NORBERT G (1161662) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:37 PM
ENRIGHT PATRICK G (1253886) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 1:09 PM
Jazz Pharmaceuticals (1232524) Subject
ORiordan Anne (1767870) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/06/2026 9:31 AM
FMR LLC (315066) Filed by
Jazz Pharmaceuticals (1232524) Subject
Form SCHEDULE 13G
08/05/2026 3:33 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/03/2026 3:16 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/03/2026 3:06 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/14/2026 3:36 PM
Jazz Pharmaceuticals (1232524) Filer
Form DEFA14A
07/06/2026 5:23 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 5:27 PM
Jazz Pharmaceuticals (1232524) Issuer
Pearce Samantha (1805688) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 5:09 PM
Jazz Pharmaceuticals (1232524) Issuer
Patil Neena M (1783908) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 5:16 PM
Iannone Robert (1737329) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 5:21 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2026 5:04 PM
Jazz Pharmaceuticals (1232524) Issuer
Johnson Philip L (2013156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2026 2:55 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2026 3:45 PM
Jazz Pharmaceuticals (1232524) Issuer
Smith Mark Douglas (1756253) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2026 3:04 PM
Jazz Pharmaceuticals (1232524) Subject
Patil Neena M (1783908) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/08/2026 3:05 PM
Jazz Pharmaceuticals (1232524) Filer
Form DEF 14A
06/08/2026 3:07 PM
Jazz Pharmaceuticals (1232524) Filer
Form DEFA14A
06/05/2026 3:40 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2026 4:09 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2026 3:05 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2026 3:18 PM
Jazz Pharmaceuticals (1232524) Subject
Pearce Samantha (1805688) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2026 5:13 PM
Jazz Pharmaceuticals (1232524) Issuer
Winningham Rick E (1302443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 5:07 PM
Jazz Pharmaceuticals (1232524) Issuer
McSharry Heather Ann (1576068) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:06 PM
Jazz Pharmaceuticals (1232524) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2026 2:44 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/30/2026 10:19 AM
Jazz Pharmaceuticals (1232524) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/03/2026 4:09 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 9:20 AM
Jazz Pharmaceuticals (1232524) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/09/2026 4:21 PM
Iannone Robert (1737329) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:23 PM
Jazz Pharmaceuticals (1232524) Issuer
Pearce Samantha (1805688) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Your book is inside (Ad)

The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel

03/09/2026 4:25 PM
Henderson Mary Elizabeth (1989533) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:27 PM
Jazz Pharmaceuticals (1232524) Issuer
Johnson Philip L (2013156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:31 PM
COZADD BRUCE C (1193210) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:07 PM
Jazz Pharmaceuticals (1232524) Issuer
Patil Neena M (1783908) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:10 PM
GALA RENEE D (1607737) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:15 PM
Carr Patricia (1784606) Reporting
Jazz Pharmaceuticals (1232524) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 3:26 PM
Carr Patricia (1784606) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 1:48 PM
Carr Patricia (1784606) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 12:58 PM
Henderson Mary Elizabeth (1989533) Reporting
Jazz Pharmaceuticals (1232524) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Jazz Pharmaceuticals SEC Filings - Frequently Asked Questions

Jazz Pharmaceuticals (JAZZ) has submitted 760+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Jazz Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Jazz Pharmaceuticals's financial statements page.

The most recent filing was a Form 4 submitted on November 10, 2026. This was an insider ownership change filed by 4 - Jazz Pharmaceuticals plc (0001232524) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:JAZZ are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 11/10/2026. New filings are added as they're published.
From Our Partners